CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

May 10, 2020

Study Completion Date

July 25, 2020

Conditions
Corona Virus Infection
Interventions
DRUG

Anakinra

"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level \> 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"

Trial Locations (1)

Unknown

Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04341584 - CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection | Biotech Hunter | Biotech Hunter